Aurobindo Pharma, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), has received approval from Health Canada -- a department of the Canadian government with responsibility for national public health -- for its abbreviated new drug submission Gabapentin capsules in 100mg, 300mg and 400mg strengths.
This is Aurobindo's sixth approval from Health Canada.
Gabapentin capsules 100mg, 300mg and 400mg is the generic equivalent of Pfizer Canada Inc's Neurontin capsules 100mg, 300mg and 400mg, which falls under the central nervous system (CNS) segment indicated for the treatment of seizures in patients diagnosed with epilepsy, the company stated in a press release on Tuesday.